

Identification of Thyroid Cancer Risk Factors, Intervention and Prognosis

Wangi Thorn*

Department of Medicine, University of Peking, Beijing, China

DESCRIPTION

Thyroid cancer is a rare but severe type of cancer that affects the thyroid gland, a little butterfly-shaped organ at the front of the neck. It is a part of the endocrine system and plays a crucial role in regulating various bodily functions [1-3]. This article aims to provide an in-depth understanding of thyroid cancer, including its types, risk factors, diagnosis, and treatment options. Thyroid cancer can be categorized into several types, with the most common being papillary thyroid carcinoma, accounting for about 80% of all cases. Follicular thyroid carcinoma, medullary thyroid carcinoma, and anaplastic thyroid carcinoma are less common but more aggressive forms of the disease. Additionally, there are various subtypes and variations of these cancers, making diagnosis and treatment more complex [4]. Thyroid cancer is staged to determine its extent and guide treatment decisions. The staging system commonly used is the TNM system, which assesses the tumor size, lymph node involvement, and metastasis. Prognosis varies depending on the stage, with early-stage thyroid cancers having a generally favorable outlook and high survival rates. However, advanced-stage or aggressive forms of thyroid cancer may have a less optimistic prognosis. The exact causes remain elusive, but certain risk factors increase its likelihood. Exposure to ionizing radiation, especially during childhood, significantly heightens the risk [5-7]. Additionally, genetic factors, such as a family history of thyroid cancer or certain inherited genetic syndromes, can contribute to its development.

One of the most aspects of thyroid cancer is its silent progression. Often, there are no noticeable symptoms in the early stages, allowing the disease to advance undetected. As it grows, it may cause symptoms such as a lump or swelling in the neck, difficulty swallowing, or unexplained changes in voice. However, these symptoms can be attributed to various other conditions, making the timely diagnosis of thyroid cancer challenging.

Diagnosis typically involves a combination of physical examinations, imaging tests (like ultrasound and CT scans), and biopsy [8]. A fine-needle aspiration biopsy, in which a small sample of tissue is extracted for examination, is a common procedure. Once diagnosed, the treatment plan is personalized based on the type and stage of cancer.

Surgery, often involving partial or total thyroidectomy, is a standard approach. Post-surgery, patients may require radioactive iodine therapy to eliminate any remaining cancerous cells. In some cases, hormone replacement therapy becomes necessary to maintain the body's metabolism balance. Beyond the physical challenges, thyroid cancer inflicts emotional and psychological turmoil on patients [9-11]. The uncertainty of the future, coupled with the fear of recurrence, can lead to anxiety and depression. Moreover, the alteration in physical appearance due to surgery can affect self-esteem and body image, making it vital for patients to receive emotional support alongside medical treatment. While complete prevention might not be possible due to the complex nature of thyroid cancer, awareness and early detection can make a substantial difference [12]. Public awareness campaigns, emphasizing the importance of regular check-ups and educating individuals about risk factors, are instrumental in fostering a proactive approach. Moreover, advocating for policies that limit exposure to radiation, especially in vulnerable populations, can contribute significantly to prevention efforts [13-15].

Thyroid cancer patients depend highly on their support networks, which include family, friends, healthcare professionals, and support groups. These networks give emotional support, share experiences, and provide practical help, fostering a sense of belonging and comprehension. Online groups, in particular, have proven to be useful venues for patients to interact, exchange knowledge, and find consolation in having the support of others who understand their difficulties.

CONCLUSION

Thyroid cancer is a relatively rare but potentially serious disease that affects the thyroid gland. While it can present with few symptoms in its early stages, timely diagnosis and appropriate treatment are crucial for a favorable outcome. With advances in medical science and ongoing research, the prognosis for thyroid cancer patients has improved significantly in recent years, making it important for individuals to be aware of their risk factors and seek medical attention if they notice any concerning symptoms. Early detection and suited treatment plans remain key to successfully managing thyroid cancer and improving the quality of life for those affected by this condition.

Correspondence to: Wangi Thorn, Department of Medicine, University of Peking, Beijing, China, E-mail: wang@thorn.cn

Received: 01-Sep-2023, Manuscript No. JTDT-23-27286; **Editor assigned:** 04-Sep-2023, PreQC No. JTDT-23-27286 (PQ); **Reviewed:** 18-Sep-2023, QC No. JTDT-23-27286; **Revised:** 25-Sep-2023, Manuscript No. JTDT-23-27286 (R); **Published:** 02-Oct-2023, DOI: 10.35841/2167-7948.23.12.306

Citation: Thorn W (2023) Identification of Thyroid Cancer Risk Factors, Intervention and Prognosis. *Thyroid Disorders Ther.* 12:306.

Copyright: © 2023 Thorn W. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Li M, Meheus F, Polazzi S, Delafosse P, Borson-Chazot F, Seigneurin A, et al. The economic cost of thyroid cancer in France and the corresponding share associated with treatment of overdiagnosed cases. *Value Health*. 2023.
2. Wadsley J, Armstrong N, Bassett-Smith V, Beasley M, Chandler R, Cluny L, et al. Patient preparation and radiation protection guidance for adult patients undergoing radioiodine treatment for thyroid cancer in the UK. *Clinical Oncology*. 2023;35(1):42-56.
3. Smith ER, Frye CC, Pandian TK, Gillanders WE, Olson JA, Brown TC, et al. Molecular characteristics of isthmus papillary thyroid cancers: Supporting evidence for unfavorable clinical behavior. *Am J Surg*. 2023.
4. Russell MD, Shonka Jr DC, Noel J, Karcioğlu AS, Ahmed AH, Angelos P, et al. Preoperative Evaluation of Thyroid Cancer—a review of current best practices. *Endocr Pract*. 2023;29(10):811-821.
5. Smith ER, Frye CC, Pandian TK, Gillanders WE, Olson JA, Brown TC, et al. Molecular characteristics of isthmus papillary thyroid cancers: Supporting evidence for unfavorable clinical behavior. *Am J Surg*. 2023:S0002-9610(23)00434-438.
6. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S, 1985-1995. *Cancer*. 1998;83(12):2638-2648.
7. Li M, Meheus F, Polazzi S, Delafosse P, Borson-Chazot F, Seigneurin A, et al. The economic cost of thyroid cancer in France and the corresponding share associated with treatment of overdiagnosed cases. *Value Health*. 2023;26(8):1175-1182.
8. Machens A, Dralle H. Simultaneous medullary and papillary thyroid cancer: A Novel entity? *Ann Surg Oncol*. 2012;19:37-44.
9. Ljungberg O, Ericsson UB, Bondeson L, Thorell J. A Compound folliculareparafollicular cell carcinoma of the thyroid: a new tumor entity? *Cancer*. 1983;52:1053-1061.
10. Volante M, Papotti M, Roth J, Saremaslani P, Speel EJ, Lloyd RV, et al. Mixed medullary-follicular thyroid carcinoma. Molecular evidence for a dual origin of tumor components. *Am J Pathol*. 1999;155:1499-1509.
11. Rossi S, Fugazzola L, De Pasquale L, Braidotti P, Cirello V, Beck-Peccoz P, et al. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature. *Endocr Relat Cancer*. 2005;12:281-289.
12. Kim WG, Gong G, Kim EY, Kim TY, Hong SJ, Kim WB, et al. Concurrent occurrence of medullary thyroid carcinoma and papillary thyroid carcinoma in the same thyroid should be considered as coincidental. *Clin Endocrinol*. 2010;72(2):256-263.
13. Bergholm U, Bergstrom R, Ekblom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. *Cancer*. 1997;79:132-138.
14. Huang J, Xu SH, Li YZ, Wang Y, Li ST, et al. A study on the detection of thyroid cancer in Hashimoto's thyroiditis using computed tomography imaging radiomics. *J Appl Sci Res*. 2023;16(4):100677.
15. Chen Z, Liu X, Wang W, Zhang L, Ling W, Wang C, et al. Machine learning-aided metallomic profiling in serum and urine of thyroid cancer patients and its environmental implications. *Sci Total Environ*. 2023;895:165100.